Genenta Science SPA (Genenta Science SPA) Short-Term Debt : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA Short-Term Debt?

Genenta Science SPA's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.

Genenta Science SPA Short-Term Debt Historical Data

The historical data trend for Genenta Science SPA's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genenta Science SPA Short-Term Debt Chart

Genenta Science SPA Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Genenta Science SPA Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial				-	-	-	-	-

Genenta Science SPA Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Genenta Science SPA Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Genenta Science SPA's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Genenta Science SPA (Genenta Science SPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

K5F:Germany

Address

Via Olgettina No. 58, Milan, ITA, 20132

Website

https://www.genenta.com

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's lead product includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.